Amyotrophic lateral sclerosis is a progressive disease of the central nervous system involving motor neurons in spinal cord and cerebral cortex. Despite intensive studies, the pathogenesis is unknown and the treatment is still ineffective. A number of hypotheses for the damage to motor neurons have been postulated; viral infections, defects in the normal DNA repair mechanisms, heavy metal intoxication, immune system dysfunction' are sometimes associated with motor neuron degeneration, but do not seem to be responsible for appearance of amyotrophic lateral sclerosis in its sporadic form. During recent years, particular attention has been focused on endocrine system dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Some investigators have reported abnormal insulin, parathormone and thyroid hormone secretion in amyotrophic lateral patients.' It has been found also that tissue and cereAddress for reprint requests: Prof J Szulc-Kuberska, MD,
SUMMARY Secretion of prolactin in nine patients with amyotrophic lateral sclerosis and in seven healthy men was investigated with the use of metoclopramide stimulation and bromocriptine inhibition tests. Blood serum prolactin concentration was determined in the basal state and 30, 60 and 120 minutes after oral administration of 10 mg metoclopramide or 2-5 mg bromocriptine. A period of 3 days intervened between testing each drug in the same individual. It was shown that basal prolactin levels in amyotrophic lateral sclerosis patients and the controls did not differ significantly, whereas in the metoclopramide stimulation test seven amyotrophic lateral sclerosis patients showed a very exaggerated response. The mean value of maximal prolactin increment was 1609 90% (SD 456) in comparison with the control group 638-3% (SD 89-7) (p < 0 01). In the bromocriptine inhibition test the mean value of maximal prolactin percentage decrement was 50 4% (SD 6-1) in amyotrophic lateral sclerosis and 66-5% (SD 5-3) in the controls and this difference was statistically insignificant. These data suggest that exaggerated prolactin response 644 otrophic lateral sclerosis, confirmed by electrophysiological examination. The patients had no symptoms of any endocrine disease and routine skull radiographs were normal. The control group consisted of seven healthy men matched for age and weight. All the investigations were performed before the patients' treatment. Starting at 8.30-9.00 a.m., after an overnight fast and at least 1 h of bed rest, the patients received one tablet (10 mg) of metoclopramide (Metoclopramidum-Polfa) or one tablet (2-5 mg) of bromocriptine (Parlodel-Sandoz). Blood samples were obtained from the antecubital vein at 0, 30, 60 and 120 min after the drug administration. A period of 3 days intervened between tests of each drug in the same individual. Plasma was separated, frozen and stored at -20°C until assayed. Serum prolactin levels were determined by a double-antibody technique using RIA kits obtained from Serono Diagnostics, Switzerland. All assays were performed in duplicate within the same run. The lower limit of assay sensitivity was 2 ng/ml. The intra-and interassay coefficients of variance were less than 6% and 10%, respectively. Statistical analysis was performed by Student's t test.
Results
The detailed results of metoclopramide stimulating test in amyotrophic lateral sclerosis patients and seven healthy men are shown in the fig. The basal prolactin levels in all amyotrophic lateral sclerosis patients were in the normal range (between 3-3-14 2 ng/ml) and were not significantly different in the control group. The peak response occurred at 60 min after metoclopramide administration in both investigated groups. However, in amyotrophic lateral sclerosis patients the mean value ofmaximal prolactin Szulc-Kuberska, Stupien, Klimek, Cieslak to the drug (increase higher than 700%) which indicated a "functional" hyperprolactinaemia.
The results of dynamic changes of prolactin secretion in the bromocriptine inhibiting test are presented in the table. Bromocriptine suppressed serum prolactin levels in both tested groups with maximal inhibitory effect 120 min after the administration of the drug. The mean value of maximal serum prolactin decrement in amyotrophic lateral sclerosis patients was 50 4% (SEM 6-1) and in comparison was not significantly different from the controls (66 5, SEM 5-3).
We were able to confirm that metoclopramide is a potent stimulator of prolactin secretion not only in healthy men89 but also in patients with amyotrophic lateral sclerosis. Metoclopramide is classified as a dopamine D2 receptor blocker which causes prolactin release primarily by inhibiting the dopamine-induced hypothalamic secretion of prolactin inhibiting factor or a stimulatory effect on the release of a still unidentified prolactin releasing factor.'0 Bromocriptine, a D2 dopamine receptor agonist, inhibiting normal and inappropriate lactation by inhibiting prolactin release at the level of pituitary lactotrophs." 12 On the other hand central sites of action are indicated by observations such as the slowing of dopamine turnover in the tuberoinfundibular neurons,'3 which can be interpreted as the hypothalamic effect of the prolactin inhibitory action of bromocriptine. 
